Michel Chonchol
Concepts (695)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Renal Insufficiency, Chronic | 83 | 2024 | 566 | 10.910 |
Why?
| Polycystic Kidney, Autosomal Dominant | 32 | 2024 | 254 | 8.960 |
Why?
| Kidney Failure, Chronic | 55 | 2023 | 546 | 7.060 |
Why?
| Glomerular Filtration Rate | 88 | 2024 | 711 | 6.180 |
Why?
| Renal Dialysis | 33 | 2023 | 423 | 5.390 |
Why?
| Kidney | 47 | 2024 | 1384 | 5.130 |
Why?
| Fibroblast Growth Factors | 25 | 2020 | 169 | 5.040 |
Why?
| Cardiovascular Diseases | 57 | 2023 | 2003 | 4.370 |
Why?
| Kidney Diseases | 31 | 2023 | 382 | 4.350 |
Why?
| Vitamin D | 31 | 2022 | 381 | 3.970 |
Why?
| Hypertension | 37 | 2022 | 1242 | 2.820 |
Why?
| Vitamin D Deficiency | 13 | 2024 | 177 | 2.720 |
Why?
| Phosphates | 12 | 2024 | 179 | 2.410 |
Why?
| Endothelium, Vascular | 17 | 2021 | 901 | 2.330 |
Why?
| Kidney Calculi | 5 | 2024 | 35 | 2.320 |
Why?
| Vascular Stiffness | 17 | 2023 | 467 | 2.290 |
Why?
| Blood Pressure | 35 | 2023 | 1736 | 2.200 |
Why?
| Nutrition Surveys | 15 | 2024 | 260 | 2.190 |
Why?
| Disease Progression | 41 | 2024 | 2622 | 2.120 |
Why?
| Aged | 171 | 2025 | 21997 | 2.080 |
Why?
| Phosphorus | 13 | 2017 | 92 | 2.060 |
Why?
| Middle Aged | 166 | 2025 | 31050 | 1.950 |
Why?
| Blood Vessels | 4 | 2024 | 187 | 1.910 |
Why?
| Male | 229 | 2025 | 63456 | 1.890 |
Why?
| Uric Acid | 12 | 2021 | 161 | 1.880 |
Why?
| Nephrology | 5 | 2022 | 60 | 1.850 |
Why?
| Oxidative Stress | 18 | 2025 | 1265 | 1.840 |
Why?
| Female | 229 | 2025 | 68494 | 1.820 |
Why?
| Cholecalciferol | 6 | 2024 | 56 | 1.780 |
Why?
| Humans | 300 | 2025 | 129144 | 1.770 |
Why?
| Creatinine | 25 | 2021 | 490 | 1.730 |
Why?
| Sodium, Dietary | 4 | 2024 | 37 | 1.660 |
Why?
| Risk Factors | 89 | 2024 | 9740 | 1.640 |
Why?
| Potassium, Dietary | 3 | 2024 | 11 | 1.590 |
Why?
| Chronic Kidney Disease-Mineral and Bone Disorder | 4 | 2020 | 13 | 1.560 |
Why?
| Parathyroid Hormone | 18 | 2020 | 106 | 1.540 |
Why?
| Vascular Calcification | 8 | 2022 | 107 | 1.440 |
Why?
| Double-Blind Method | 30 | 2023 | 1874 | 1.420 |
Why?
| Dietary Supplements | 10 | 2021 | 534 | 1.400 |
Why?
| Biomarkers | 43 | 2024 | 3963 | 1.310 |
Why?
| Lanthanum | 4 | 2024 | 13 | 1.290 |
Why?
| Calcium | 13 | 2020 | 1211 | 1.210 |
Why?
| Inflammation | 20 | 2024 | 2735 | 1.210 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 7 | 2023 | 430 | 1.190 |
Why?
| Adult | 82 | 2025 | 35469 | 1.180 |
Why?
| Fatty Liver | 10 | 2013 | 230 | 1.180 |
Why?
| Antihypertensive Agents | 14 | 2021 | 485 | 1.180 |
Why?
| Brachial Artery | 11 | 2018 | 192 | 1.140 |
Why?
| Coronary Disease | 7 | 2010 | 385 | 1.100 |
Why?
| Bacterial Infections | 3 | 2016 | 235 | 1.090 |
Why?
| Naphthalenes | 4 | 2015 | 57 | 1.090 |
Why?
| Prevalence | 27 | 2024 | 2554 | 1.080 |
Why?
| Cross-Sectional Studies | 40 | 2024 | 5044 | 1.080 |
Why?
| Vascular Diseases | 7 | 2021 | 240 | 1.010 |
Why?
| Adrenergic beta-Antagonists | 7 | 2011 | 321 | 1.010 |
Why?
| Coronary Artery Disease | 11 | 2022 | 679 | 0.990 |
Why?
| Prospective Studies | 41 | 2023 | 7117 | 0.970 |
Why?
| Pulse Wave Analysis | 10 | 2023 | 248 | 0.970 |
Why?
| Hyperparathyroidism, Secondary | 4 | 2009 | 12 | 0.940 |
Why?
| Cognition | 6 | 2023 | 1122 | 0.940 |
Why?
| Minerals | 6 | 2022 | 39 | 0.900 |
Why?
| Acute Kidney Injury | 10 | 2022 | 789 | 0.890 |
Why?
| Cohort Studies | 32 | 2024 | 5408 | 0.890 |
Why?
| Vasodilation | 7 | 2025 | 476 | 0.880 |
Why?
| Curcumin | 2 | 2021 | 29 | 0.870 |
Why?
| Intra-Abdominal Fat | 1 | 2024 | 88 | 0.840 |
Why?
| Aged, 80 and over | 43 | 2023 | 7037 | 0.830 |
Why?
| Pregnancy Complications | 3 | 2018 | 493 | 0.820 |
Why?
| Anemia | 5 | 2020 | 160 | 0.820 |
Why?
| Follow-Up Studies | 37 | 2020 | 4882 | 0.820 |
Why?
| Cognitive Dysfunction | 2 | 2018 | 346 | 0.810 |
Why?
| Proportional Hazards Models | 30 | 2019 | 1197 | 0.810 |
Why?
| Albuminuria | 13 | 2022 | 183 | 0.790 |
Why?
| Incidence | 28 | 2021 | 2635 | 0.790 |
Why?
| Vascular Surgical Procedures | 13 | 2011 | 294 | 0.770 |
Why?
| Non-alcoholic Fatty Liver Disease | 9 | 2016 | 260 | 0.750 |
Why?
| Atherosclerosis | 8 | 2021 | 402 | 0.750 |
Why?
| Metformin | 2 | 2024 | 316 | 0.730 |
Why?
| Kidney Tubules | 5 | 2024 | 114 | 0.720 |
Why?
| Renal Insufficiency | 6 | 2023 | 149 | 0.720 |
Why?
| Kidney Function Tests | 12 | 2017 | 152 | 0.710 |
Why?
| Kidney Transplantation | 3 | 2022 | 670 | 0.710 |
Why?
| Vitamins | 3 | 2022 | 173 | 0.710 |
Why?
| Calcimimetic Agents | 1 | 2020 | 3 | 0.700 |
Why?
| Hyponatremia | 2 | 2018 | 39 | 0.700 |
Why?
| Calcitriol | 2 | 2018 | 54 | 0.690 |
Why?
| Cystatin C | 7 | 2013 | 64 | 0.690 |
Why?
| Sodium | 2 | 2019 | 205 | 0.690 |
Why?
| Time Factors | 30 | 2022 | 6541 | 0.680 |
Why?
| Bicarbonates | 5 | 2023 | 42 | 0.670 |
Why?
| Systole | 8 | 2020 | 191 | 0.670 |
Why?
| Bone Diseases | 1 | 2020 | 57 | 0.660 |
Why?
| Renal Artery Obstruction | 3 | 2014 | 29 | 0.660 |
Why?
| Renin-Angiotensin System | 3 | 2017 | 82 | 0.660 |
Why?
| Odds Ratio | 13 | 2024 | 1017 | 0.650 |
Why?
| Sodium Bicarbonate | 2 | 2023 | 37 | 0.650 |
Why?
| Prognosis | 27 | 2021 | 3766 | 0.650 |
Why?
| Interleukin-1 | 3 | 2019 | 959 | 0.640 |
Why?
| United States | 35 | 2024 | 13825 | 0.630 |
Why?
| Overweight | 2 | 2021 | 531 | 0.630 |
Why?
| Cause of Death | 6 | 2018 | 392 | 0.620 |
Why?
| Young Adult | 24 | 2025 | 12385 | 0.620 |
Why?
| Spironolactone | 1 | 2019 | 30 | 0.610 |
Why?
| Treatment Outcome | 38 | 2021 | 10192 | 0.610 |
Why?
| Chronic Disease | 19 | 2017 | 1714 | 0.610 |
Why?
| Mineralocorticoid Receptor Antagonists | 1 | 2019 | 46 | 0.610 |
Why?
| Acidosis | 2 | 2018 | 89 | 0.600 |
Why?
| Simvastatin | 3 | 2014 | 60 | 0.590 |
Why?
| Accidental Falls | 1 | 2020 | 169 | 0.590 |
Why?
| Hemoglobins | 4 | 2009 | 339 | 0.590 |
Why?
| Endothelial Cells | 5 | 2023 | 746 | 0.590 |
Why?
| Heart Diseases | 4 | 2015 | 350 | 0.590 |
Why?
| Calcium, Dietary | 2 | 2009 | 56 | 0.580 |
Why?
| Caloric Restriction | 4 | 2024 | 111 | 0.580 |
Why?
| Interleukin-6 | 3 | 2020 | 720 | 0.580 |
Why?
| Hypertrophy, Left Ventricular | 4 | 2017 | 126 | 0.580 |
Why?
| Frailty | 1 | 2020 | 152 | 0.570 |
Why?
| Arterial Pressure | 1 | 2018 | 118 | 0.570 |
Why?
| Death, Sudden, Cardiac | 5 | 2015 | 179 | 0.570 |
Why?
| Recombinant Fusion Proteins | 2 | 2017 | 648 | 0.570 |
Why?
| Obesity | 4 | 2021 | 2879 | 0.560 |
Why?
| Carotid Artery Diseases | 3 | 2021 | 64 | 0.550 |
Why?
| Calcinosis | 6 | 2017 | 231 | 0.550 |
Why?
| Logistic Models | 12 | 2024 | 1982 | 0.540 |
Why?
| Multivariate Analysis | 14 | 2017 | 1495 | 0.540 |
Why?
| Longitudinal Studies | 17 | 2020 | 2716 | 0.540 |
Why?
| Pregnancy Outcome | 3 | 2018 | 389 | 0.530 |
Why?
| Bone Density | 5 | 2017 | 462 | 0.530 |
Why?
| Calciphylaxis | 1 | 2016 | 2 | 0.520 |
Why?
| Conservative Treatment | 1 | 2017 | 32 | 0.520 |
Why?
| Uremia | 1 | 2016 | 14 | 0.520 |
Why?
| Sodium Chloride | 1 | 2017 | 137 | 0.510 |
Why?
| Primary Prevention | 3 | 2018 | 188 | 0.500 |
Why?
| Diabetic Nephropathies | 5 | 2013 | 284 | 0.500 |
Why?
| Angiotensin-Converting Enzyme Inhibitors | 5 | 2018 | 198 | 0.500 |
Why?
| Fluid Therapy | 1 | 2017 | 133 | 0.500 |
Why?
| Hyperuricemia | 5 | 2018 | 44 | 0.490 |
Why?
| Diet, Sodium-Restricted | 4 | 2020 | 34 | 0.490 |
Why?
| Retrospective Studies | 33 | 2024 | 14450 | 0.490 |
Why?
| Myocardial Infarction | 10 | 2017 | 1021 | 0.480 |
Why?
| Ventricular Dysfunction, Left | 6 | 2014 | 385 | 0.480 |
Why?
| Peripheral Vascular Diseases | 7 | 2012 | 101 | 0.470 |
Why?
| Diabetes Mellitus, Type 2 | 10 | 2012 | 2439 | 0.470 |
Why?
| Liver | 2 | 2016 | 1839 | 0.470 |
Why?
| Comorbidity | 13 | 2018 | 1544 | 0.470 |
Why?
| Undocumented Immigrants | 3 | 2023 | 48 | 0.470 |
Why?
| Diabetes Complications | 6 | 2018 | 224 | 0.470 |
Why?
| Peripheral Arterial Disease | 7 | 2021 | 457 | 0.460 |
Why?
| Risk Assessment | 24 | 2021 | 3231 | 0.450 |
Why?
| Fructose | 2 | 2016 | 106 | 0.450 |
Why?
| Survival Rate | 14 | 2020 | 1869 | 0.450 |
Why?
| Pyrazoles | 2 | 2014 | 404 | 0.450 |
Why?
| Cardiovascular Agents | 4 | 2013 | 156 | 0.440 |
Why?
| Pyridines | 2 | 2014 | 478 | 0.440 |
Why?
| Body Mass Index | 10 | 2024 | 2272 | 0.430 |
Why?
| Magnetic Resonance Imaging | 7 | 2024 | 3386 | 0.430 |
Why?
| Hyperphosphatemia | 4 | 2020 | 15 | 0.430 |
Why?
| Ankle Brachial Index | 4 | 2014 | 36 | 0.420 |
Why?
| Sodium Nitrite | 3 | 2021 | 39 | 0.420 |
Why?
| C-Reactive Protein | 8 | 2018 | 400 | 0.410 |
Why?
| Pneumonia, Bacterial | 1 | 2014 | 115 | 0.410 |
Why?
| Diet | 3 | 2024 | 1212 | 0.410 |
Why?
| TRPP Cation Channels | 5 | 2022 | 79 | 0.400 |
Why?
| Nephrolithiasis | 1 | 2012 | 10 | 0.400 |
Why?
| Community-Acquired Infections | 1 | 2014 | 160 | 0.390 |
Why?
| Hemostasis | 2 | 2009 | 79 | 0.390 |
Why?
| Radius | 1 | 2012 | 36 | 0.390 |
Why?
| Magnesium | 2 | 2014 | 153 | 0.380 |
Why?
| Chi-Square Distribution | 10 | 2017 | 514 | 0.380 |
Why?
| Randomized Controlled Trials as Topic | 11 | 2021 | 1363 | 0.380 |
Why?
| Metabolic Syndrome | 6 | 2014 | 339 | 0.380 |
Why?
| Carotid Arteries | 4 | 2018 | 196 | 0.380 |
Why?
| Internship and Residency | 2 | 2020 | 1046 | 0.370 |
Why?
| Health Status | 3 | 2015 | 754 | 0.370 |
Why?
| Disease Management | 1 | 2015 | 588 | 0.370 |
Why?
| Heart Ventricles | 2 | 2013 | 781 | 0.360 |
Why?
| Coronary Artery Bypass | 3 | 2014 | 224 | 0.360 |
Why?
| Hypothyroidism | 2 | 2009 | 70 | 0.360 |
Why?
| Independent Living | 5 | 2018 | 97 | 0.360 |
Why?
| Kaplan-Meier Estimate | 14 | 2018 | 851 | 0.360 |
Why?
| Blood Coagulation Disorders | 2 | 2010 | 167 | 0.350 |
Why?
| Health Surveys | 3 | 2014 | 493 | 0.350 |
Why?
| Resistance Training | 2 | 2023 | 151 | 0.350 |
Why?
| Dementia | 3 | 2023 | 225 | 0.350 |
Why?
| Insulin Resistance | 6 | 2013 | 1165 | 0.350 |
Why?
| NAD | 2 | 2023 | 75 | 0.350 |
Why?
| Physical Fitness | 1 | 2012 | 203 | 0.350 |
Why?
| Case-Control Studies | 11 | 2021 | 3372 | 0.340 |
Why?
| Homeostasis | 5 | 2018 | 605 | 0.340 |
Why?
| Hip Fractures | 3 | 2017 | 82 | 0.330 |
Why?
| Mortality | 5 | 2020 | 307 | 0.330 |
Why?
| Hypercapnia | 3 | 2025 | 50 | 0.330 |
Why?
| Ischemia | 3 | 2011 | 405 | 0.330 |
Why?
| Weight Loss | 1 | 2015 | 732 | 0.330 |
Why?
| Dyslipidemias | 2 | 2013 | 177 | 0.330 |
Why?
| Lovastatin | 1 | 2009 | 37 | 0.330 |
Why?
| Zinc | 1 | 2012 | 285 | 0.320 |
Why?
| Polycystic Kidney Diseases | 2 | 2023 | 68 | 0.320 |
Why?
| Blood Coagulation | 3 | 2011 | 238 | 0.320 |
Why?
| gamma-Glutamyltransferase | 1 | 2009 | 42 | 0.320 |
Why?
| Hospitalization | 3 | 2016 | 2052 | 0.320 |
Why?
| Endocrine System Diseases | 1 | 2009 | 33 | 0.320 |
Why?
| Fibrinolysis | 2 | 2011 | 137 | 0.310 |
Why?
| Aging | 5 | 2025 | 1774 | 0.310 |
Why?
| Hospitals, Veterans | 2 | 2008 | 243 | 0.310 |
Why?
| Hepatitis A Virus Cellular Receptor 1 | 4 | 2024 | 42 | 0.310 |
Why?
| Lipocalin-2 | 4 | 2024 | 75 | 0.310 |
Why?
| Uromodulin | 5 | 2022 | 21 | 0.300 |
Why?
| Regional Blood Flow | 5 | 2017 | 463 | 0.300 |
Why?
| Bilirubin | 1 | 2009 | 96 | 0.300 |
Why?
| Bone and Bones | 2 | 2012 | 294 | 0.290 |
Why?
| Sepsis | 1 | 2014 | 572 | 0.290 |
Why?
| Phosphorus Metabolism Disorders | 1 | 2007 | 1 | 0.290 |
Why?
| Severity of Illness Index | 12 | 2020 | 2736 | 0.290 |
Why?
| Patient Navigation | 2 | 2019 | 78 | 0.280 |
Why?
| Coronary Angiography | 3 | 2012 | 305 | 0.280 |
Why?
| Aorta | 3 | 2021 | 408 | 0.270 |
Why?
| Ultrasonography | 6 | 2013 | 712 | 0.270 |
Why?
| Adolescent | 14 | 2023 | 20297 | 0.270 |
Why?
| Metabolomics | 4 | 2022 | 652 | 0.270 |
Why?
| Aortic Aneurysm, Abdominal | 6 | 2011 | 132 | 0.270 |
Why?
| Pravastatin | 2 | 2023 | 40 | 0.260 |
Why?
| Brain | 2 | 2018 | 2668 | 0.260 |
Why?
| Angiotensin Receptor Antagonists | 2 | 2018 | 89 | 0.260 |
Why?
| Infant Mortality | 2 | 2018 | 103 | 0.260 |
Why?
| Electric Countershock | 1 | 2007 | 105 | 0.260 |
Why?
| Infant, Low Birth Weight | 2 | 2018 | 135 | 0.260 |
Why?
| Professional Competence | 1 | 2006 | 94 | 0.250 |
Why?
| Thrombosis | 1 | 2009 | 343 | 0.250 |
Why?
| Coronary Vessels | 3 | 2022 | 239 | 0.250 |
Why?
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 757 | 0.240 |
Why?
| Fasting | 4 | 2023 | 267 | 0.240 |
Why?
| Anticholesteremic Agents | 1 | 2007 | 150 | 0.240 |
Why?
| Respiratory Muscles | 2 | 2023 | 32 | 0.240 |
Why?
| Deoxycholic Acid | 3 | 2022 | 14 | 0.240 |
Why?
| Carotid Artery, Internal | 1 | 2025 | 41 | 0.230 |
Why?
| Cognition Disorders | 3 | 2017 | 505 | 0.230 |
Why?
| Survival Analysis | 6 | 2019 | 1268 | 0.230 |
Why?
| Beer | 1 | 2024 | 7 | 0.230 |
Why?
| Wine | 1 | 2024 | 11 | 0.230 |
Why?
| Blood Pressure Determination | 3 | 2020 | 148 | 0.230 |
Why?
| Pre-Eclampsia | 2 | 2018 | 187 | 0.230 |
Why?
| Cross-Over Studies | 5 | 2018 | 520 | 0.230 |
Why?
| Tryptophan | 2 | 2023 | 177 | 0.230 |
Why?
| Nitric Oxide | 5 | 2023 | 895 | 0.230 |
Why?
| Antidiuretic Hormone Receptor Antagonists | 1 | 2024 | 8 | 0.230 |
Why?
| Quality of Life | 4 | 2020 | 2680 | 0.220 |
Why?
| Diabetes Mellitus, Type 1 | 7 | 2014 | 3628 | 0.220 |
Why?
| Cerebrovascular Circulation | 3 | 2025 | 227 | 0.220 |
Why?
| Linear Models | 6 | 2017 | 819 | 0.220 |
Why?
| Obesity, Abdominal | 1 | 2024 | 47 | 0.220 |
Why?
| Nephrotic Syndrome | 1 | 2003 | 28 | 0.210 |
Why?
| Nutritional Status | 2 | 2018 | 328 | 0.210 |
Why?
| Diet, Ketogenic | 1 | 2023 | 36 | 0.210 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2020 | 338 | 0.210 |
Why?
| Mitochondria | 2 | 2021 | 876 | 0.210 |
Why?
| Confidence Intervals | 3 | 2012 | 316 | 0.210 |
Why?
| Animals | 15 | 2023 | 35286 | 0.210 |
Why?
| Military Personnel | 1 | 2009 | 515 | 0.210 |
Why?
| Atrial Fibrillation | 2 | 2020 | 376 | 0.200 |
Why?
| Metabolome | 3 | 2022 | 338 | 0.200 |
Why?
| Colorado | 9 | 2021 | 4402 | 0.200 |
Why?
| Drug Therapy, Combination | 6 | 2020 | 1040 | 0.200 |
Why?
| Human Umbilical Vein Endothelial Cells | 2 | 2021 | 102 | 0.200 |
Why?
| Recovery of Function | 3 | 2017 | 641 | 0.200 |
Why?
| Antioxidants | 2 | 2018 | 558 | 0.200 |
Why?
| Guideline Adherence | 1 | 2006 | 525 | 0.200 |
Why?
| Compassion Fatigue | 1 | 2022 | 29 | 0.200 |
Why?
| Child | 9 | 2023 | 20768 | 0.200 |
Why?
| Up-Regulation | 5 | 2019 | 838 | 0.190 |
Why?
| Troponin T | 3 | 2012 | 57 | 0.190 |
Why?
| Pilot Projects | 4 | 2024 | 1583 | 0.190 |
Why?
| Diastole | 3 | 2013 | 148 | 0.190 |
Why?
| Receptor Protein-Tyrosine Kinases | 2 | 2014 | 231 | 0.190 |
Why?
| Heart Failure | 8 | 2017 | 2129 | 0.190 |
Why?
| Physicians | 2 | 2022 | 859 | 0.190 |
Why?
| Breathing Exercises | 1 | 2021 | 20 | 0.180 |
Why?
| Inhalation | 1 | 2021 | 28 | 0.180 |
Why?
| Exercise Tolerance | 1 | 2023 | 273 | 0.180 |
Why?
| Niacinamide | 2 | 2020 | 75 | 0.180 |
Why?
| Diabetes Mellitus | 4 | 2020 | 1000 | 0.180 |
Why?
| Predictive Value of Tests | 11 | 2019 | 1943 | 0.180 |
Why?
| Toxins, Biological | 1 | 2020 | 11 | 0.180 |
Why?
| Stroke | 4 | 2017 | 1070 | 0.180 |
Why?
| Education | 2 | 2018 | 100 | 0.180 |
Why?
| Propensity Score | 2 | 2019 | 263 | 0.180 |
Why?
| Parathyroidectomy | 1 | 2020 | 7 | 0.180 |
Why?
| Culturally Competent Care | 1 | 2021 | 57 | 0.180 |
Why?
| Osteoporotic Fractures | 2 | 2012 | 56 | 0.170 |
Why?
| Attitude of Health Personnel | 2 | 2018 | 1094 | 0.170 |
Why?
| Neutrophils | 1 | 2006 | 1207 | 0.170 |
Why?
| Motor Activity | 2 | 2015 | 675 | 0.170 |
Why?
| Intestinal Absorption | 1 | 2021 | 99 | 0.170 |
Why?
| Propanolamines | 2 | 2011 | 97 | 0.170 |
Why?
| Communication Barriers | 1 | 2021 | 98 | 0.170 |
Why?
| Netherlands | 8 | 2012 | 77 | 0.170 |
Why?
| Feasibility Studies | 2 | 2021 | 865 | 0.170 |
Why?
| Sevelamer | 1 | 2020 | 9 | 0.170 |
Why?
| Plaque, Atherosclerotic | 1 | 2021 | 55 | 0.170 |
Why?
| Carotid Intima-Media Thickness | 2 | 2018 | 90 | 0.170 |
Why?
| Allopurinol | 2 | 2018 | 62 | 0.170 |
Why?
| Hypokalemia | 1 | 2020 | 24 | 0.170 |
Why?
| Placebos | 2 | 2012 | 201 | 0.170 |
Why?
| Socioeconomic Factors | 3 | 2020 | 1208 | 0.170 |
Why?
| Hyperkalemia | 1 | 2020 | 24 | 0.170 |
Why?
| Tunica Intima | 3 | 2010 | 84 | 0.160 |
Why?
| Organ Size | 2 | 2017 | 445 | 0.160 |
Why?
| Energy Metabolism | 2 | 2024 | 873 | 0.160 |
Why?
| Diffusion Magnetic Resonance Imaging | 1 | 2020 | 97 | 0.160 |
Why?
| Age Factors | 8 | 2018 | 3140 | 0.160 |
Why?
| Age Distribution | 2 | 2012 | 372 | 0.160 |
Why?
| Preoperative Period | 4 | 2014 | 114 | 0.160 |
Why?
| Acetates | 1 | 2020 | 100 | 0.160 |
Why?
| Sex Distribution | 2 | 2012 | 359 | 0.160 |
Why?
| Focus Groups | 2 | 2020 | 450 | 0.160 |
Why?
| Ambulatory Care Facilities | 1 | 2021 | 226 | 0.160 |
Why?
| Patient Care Planning | 1 | 2020 | 146 | 0.160 |
Why?
| Adiposity | 1 | 2024 | 504 | 0.160 |
Why?
| Lipoproteins, HDL | 1 | 2019 | 85 | 0.150 |
Why?
| Calcification, Physiologic | 1 | 2018 | 33 | 0.150 |
Why?
| Neuroimaging | 2 | 2018 | 278 | 0.150 |
Why?
| Immunosuppressive Agents | 1 | 2003 | 854 | 0.150 |
Why?
| Carnitine | 1 | 2018 | 76 | 0.150 |
Why?
| Potassium | 2 | 2020 | 143 | 0.150 |
Why?
| Mice | 8 | 2023 | 16905 | 0.150 |
Why?
| Information Seeking Behavior | 1 | 2018 | 33 | 0.150 |
Why?
| Infant, Newborn | 4 | 2018 | 5736 | 0.150 |
Why?
| Scandinavian and Nordic Countries | 2 | 2008 | 12 | 0.150 |
Why?
| Electrocardiography | 5 | 2020 | 608 | 0.150 |
Why?
| Reactive Oxygen Species | 4 | 2023 | 593 | 0.150 |
Why?
| Fellowships and Scholarships | 2 | 2020 | 273 | 0.140 |
Why?
| Cholesterol, HDL | 4 | 2013 | 205 | 0.140 |
Why?
| Alcohol Drinking | 1 | 2024 | 763 | 0.140 |
Why?
| Postoperative Complications | 6 | 2014 | 2472 | 0.140 |
Why?
| Healthy Lifestyle | 1 | 2018 | 32 | 0.140 |
Why?
| Healthy Aging | 1 | 2018 | 34 | 0.140 |
Why?
| Pain | 2 | 2020 | 786 | 0.140 |
Why?
| Health Services Accessibility | 3 | 2021 | 899 | 0.140 |
Why?
| Bone Diseases, Metabolic | 1 | 2018 | 57 | 0.140 |
Why?
| Emergency Treatment | 1 | 2018 | 111 | 0.140 |
Why?
| Adaptive Immunity | 1 | 2018 | 161 | 0.140 |
Why?
| Femoral Artery | 1 | 2018 | 173 | 0.140 |
Why?
| Death | 1 | 2018 | 117 | 0.140 |
Why?
| Hemodialysis Solutions | 1 | 2017 | 3 | 0.140 |
Why?
| Peer Group | 1 | 2019 | 225 | 0.130 |
Why?
| Preoperative Care | 2 | 2010 | 338 | 0.130 |
Why?
| 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 2 | 2013 | 17 | 0.130 |
Why?
| Congenital Abnormalities | 1 | 2017 | 74 | 0.130 |
Why?
| Vasopressins | 1 | 2017 | 64 | 0.130 |
Why?
| Neuropsychological Tests | 2 | 2018 | 1014 | 0.130 |
Why?
| Burnout, Professional | 1 | 2022 | 404 | 0.130 |
Why?
| Immunity, Humoral | 1 | 2017 | 118 | 0.130 |
Why?
| Living Donors | 1 | 2018 | 286 | 0.130 |
Why?
| Trehalose | 1 | 2016 | 30 | 0.130 |
Why?
| Liver Transplantation | 1 | 2003 | 831 | 0.130 |
Why?
| Postoperative Period | 3 | 2011 | 329 | 0.130 |
Why?
| Cholesterol, LDL | 3 | 2013 | 358 | 0.130 |
Why?
| Bile Acids and Salts | 1 | 2017 | 195 | 0.130 |
Why?
| Mutation | 3 | 2022 | 3705 | 0.120 |
Why?
| Heart Arrest | 2 | 2016 | 320 | 0.120 |
Why?
| Vascular Resistance | 2 | 2014 | 370 | 0.120 |
Why?
| Lipogenesis | 1 | 2016 | 59 | 0.120 |
Why?
| Absorptiometry, Photon | 2 | 2017 | 248 | 0.120 |
Why?
| Heart Valve Diseases | 1 | 2017 | 152 | 0.120 |
Why?
| Risk Reduction Behavior | 2 | 2015 | 209 | 0.120 |
Why?
| Heart Rate | 2 | 2011 | 802 | 0.120 |
Why?
| Immunity, Cellular | 1 | 2017 | 265 | 0.120 |
Why?
| Phosphatidylethanolamines | 1 | 2015 | 74 | 0.120 |
Why?
| Stearoyl-CoA Desaturase | 1 | 2015 | 65 | 0.120 |
Why?
| Pregnancy | 3 | 2018 | 6392 | 0.120 |
Why?
| Global Health | 2 | 2015 | 327 | 0.120 |
Why?
| Communicable Diseases | 1 | 2017 | 147 | 0.120 |
Why?
| Analysis of Variance | 3 | 2012 | 1288 | 0.120 |
Why?
| Peptides | 1 | 2020 | 923 | 0.120 |
Why?
| Endoplasmic Reticulum Stress | 1 | 2015 | 101 | 0.120 |
Why?
| Frail Elderly | 1 | 2016 | 120 | 0.120 |
Why?
| Obstetric Labor, Premature | 1 | 2015 | 35 | 0.120 |
Why?
| Maternal Mortality | 1 | 2015 | 40 | 0.120 |
Why?
| Urinary Tract Infections | 1 | 2016 | 151 | 0.120 |
Why?
| Risk | 5 | 2019 | 851 | 0.120 |
Why?
| Aorta, Abdominal | 2 | 2012 | 43 | 0.120 |
Why?
| Fibroblast Growth Factor 3 | 1 | 2014 | 3 | 0.110 |
Why?
| Metabolic Diseases | 2 | 2014 | 104 | 0.110 |
Why?
| Serine | 1 | 2015 | 138 | 0.110 |
Why?
| Dose-Response Relationship, Drug | 4 | 2013 | 2008 | 0.110 |
Why?
| Italy | 5 | 2014 | 99 | 0.110 |
Why?
| 24,25-Dihydroxyvitamin D 3 | 1 | 2014 | 2 | 0.110 |
Why?
| Acetylcholine | 3 | 2023 | 183 | 0.110 |
Why?
| Transforming Growth Factor beta | 1 | 2017 | 455 | 0.110 |
Why?
| Transcription Factor CHOP | 1 | 2014 | 30 | 0.110 |
Why?
| Estrogen Replacement Therapy | 2 | 2014 | 137 | 0.110 |
Why?
| Renal Artery | 1 | 2014 | 34 | 0.110 |
Why?
| Inflammation Mediators | 1 | 2017 | 504 | 0.110 |
Why?
| Infant, Small for Gestational Age | 1 | 2015 | 85 | 0.110 |
Why?
| Organophosphonates | 1 | 2014 | 91 | 0.110 |
Why?
| Sodium Chloride, Dietary | 1 | 2014 | 31 | 0.110 |
Why?
| Linoleic Acids, Conjugated | 1 | 2013 | 8 | 0.110 |
Why?
| Endothelium | 1 | 2014 | 121 | 0.110 |
Why?
| Tocopherols | 1 | 2013 | 25 | 0.110 |
Why?
| Steroid Hydroxylases | 1 | 2013 | 22 | 0.110 |
Why?
| Antibodies, Monoclonal | 1 | 2020 | 1363 | 0.110 |
Why?
| NF-kappa B p50 Subunit | 1 | 2013 | 24 | 0.110 |
Why?
| Aortic Valve Stenosis | 2 | 2017 | 218 | 0.110 |
Why?
| Bufanolides | 1 | 2013 | 4 | 0.110 |
Why?
| Observational Studies as Topic | 1 | 2014 | 110 | 0.110 |
Why?
| Statistics as Topic | 2 | 2017 | 305 | 0.100 |
Why?
| Sex Factors | 5 | 2018 | 1964 | 0.100 |
Why?
| Premature Birth | 1 | 2017 | 314 | 0.100 |
Why?
| Healthcare Disparities | 1 | 2019 | 574 | 0.100 |
Why?
| Glucose | 1 | 2018 | 1000 | 0.100 |
Why?
| Cesarean Section | 1 | 2015 | 181 | 0.100 |
Why?
| Education, Medical, Graduate | 1 | 2017 | 438 | 0.100 |
Why?
| Gastrointestinal Microbiome | 1 | 2020 | 640 | 0.100 |
Why?
| Enzyme Inhibitors | 1 | 2016 | 827 | 0.100 |
Why?
| Adenine | 1 | 2014 | 256 | 0.100 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2018 | 854 | 0.100 |
Why?
| Institutionalization | 1 | 2012 | 12 | 0.100 |
Why?
| Ferric Compounds | 1 | 2012 | 46 | 0.100 |
Why?
| Spinal Fractures | 1 | 2013 | 82 | 0.100 |
Why?
| Causality | 2 | 2011 | 117 | 0.100 |
Why?
| Glycation End Products, Advanced | 1 | 2012 | 76 | 0.100 |
Why?
| Chitinase-3-Like Protein 1 | 2 | 2024 | 19 | 0.100 |
Why?
| Postoperative Care | 2 | 2010 | 241 | 0.090 |
Why?
| Intensive Care Units, Neonatal | 1 | 2015 | 226 | 0.090 |
Why?
| Endoplasmic Reticulum | 1 | 2014 | 261 | 0.090 |
Why?
| Echocardiography, Stress | 2 | 2010 | 20 | 0.090 |
Why?
| Tunica Media | 2 | 2010 | 38 | 0.090 |
Why?
| Kynurenine | 2 | 2023 | 113 | 0.090 |
Why?
| Aortic Aneurysm | 1 | 2012 | 65 | 0.090 |
Why?
| Cytokines | 2 | 2018 | 2012 | 0.090 |
Why?
| Sympathetic Nervous System | 2 | 2015 | 174 | 0.090 |
Why?
| Meta-Analysis as Topic | 1 | 2012 | 170 | 0.090 |
Why?
| Dietary Fiber | 1 | 2011 | 51 | 0.090 |
Why?
| Chemokine CCL2 | 2 | 2024 | 117 | 0.090 |
Why?
| Hospital Mortality | 2 | 2014 | 846 | 0.090 |
Why?
| International Classification of Diseases | 1 | 2012 | 122 | 0.090 |
Why?
| Lung Neoplasms | 2 | 2014 | 2340 | 0.090 |
Why?
| Hemostatic Disorders | 1 | 2011 | 1 | 0.090 |
Why?
| Models, Biological | 3 | 2024 | 1722 | 0.090 |
Why?
| Drug Combinations | 1 | 2012 | 330 | 0.090 |
Why?
| Cardiovascular System | 3 | 2020 | 136 | 0.090 |
Why?
| Heart Failure, Systolic | 1 | 2010 | 25 | 0.090 |
Why?
| Infant, Premature | 1 | 2015 | 541 | 0.090 |
Why?
| Muscle Strength | 2 | 2023 | 303 | 0.090 |
Why?
| Gout | 1 | 2010 | 33 | 0.090 |
Why?
| Natriuretic Peptide, Brain | 1 | 2010 | 99 | 0.090 |
Why?
| Carbazoles | 1 | 2010 | 84 | 0.080 |
Why?
| Ticlopidine | 1 | 2010 | 54 | 0.080 |
Why?
| Thinness | 1 | 2010 | 89 | 0.080 |
Why?
| Alpha-Globulins | 2 | 2020 | 20 | 0.080 |
Why?
| beta 2-Microglobulin | 2 | 2020 | 49 | 0.080 |
Why?
| Aneurysm | 1 | 2009 | 30 | 0.080 |
Why?
| Proteinuria | 2 | 2014 | 91 | 0.080 |
Why?
| Nisoldipine | 1 | 2009 | 7 | 0.080 |
Why?
| Length of Stay | 1 | 2015 | 1120 | 0.080 |
Why?
| Enalapril | 1 | 2009 | 16 | 0.080 |
Why?
| Arterial Occlusive Diseases | 1 | 2009 | 80 | 0.080 |
Why?
| Mice, Inbred C57BL | 4 | 2023 | 5438 | 0.080 |
Why?
| Cerebrovascular Disorders | 1 | 2009 | 90 | 0.080 |
Why?
| Texas | 1 | 2009 | 228 | 0.080 |
Why?
| Genetic Loci | 1 | 2010 | 275 | 0.080 |
Why?
| Qualitative Research | 3 | 2021 | 1214 | 0.080 |
Why?
| Delphi Technique | 2 | 2020 | 225 | 0.080 |
Why?
| Radioisotope Renography | 1 | 2008 | 4 | 0.080 |
Why?
| Regression Analysis | 3 | 2019 | 992 | 0.080 |
Why?
| Tomography, Spiral Computed | 1 | 2008 | 27 | 0.080 |
Why?
| Thrombophilia | 1 | 2009 | 81 | 0.080 |
Why?
| Ultrasonography, Doppler, Color | 1 | 2008 | 38 | 0.080 |
Why?
| Chelating Agents | 2 | 2020 | 68 | 0.080 |
Why?
| Population Groups | 1 | 2009 | 60 | 0.080 |
Why?
| Databases as Topic | 1 | 2008 | 59 | 0.070 |
Why?
| Perindopril | 1 | 2007 | 1 | 0.070 |
Why?
| Diabetic Retinopathy | 1 | 2010 | 177 | 0.070 |
Why?
| Demography | 1 | 2009 | 279 | 0.070 |
Why?
| Infant | 3 | 2018 | 8975 | 0.070 |
Why?
| Osteogenesis | 2 | 2021 | 172 | 0.070 |
Why?
| Adenocarcinoma | 1 | 2014 | 891 | 0.070 |
Why?
| Protein Kinase Inhibitors | 1 | 2013 | 885 | 0.070 |
Why?
| Endpoint Determination | 1 | 2008 | 76 | 0.070 |
Why?
| Aspirin | 1 | 2010 | 380 | 0.070 |
Why?
| Data Interpretation, Statistical | 1 | 2009 | 336 | 0.070 |
Why?
| Mice, Knockout | 3 | 2023 | 2871 | 0.070 |
Why?
| Estradiol | 1 | 2010 | 493 | 0.070 |
Why?
| Testosterone | 1 | 2010 | 372 | 0.070 |
Why?
| Peptide Fragments | 1 | 2010 | 692 | 0.070 |
Why?
| Platelet Aggregation Inhibitors | 1 | 2010 | 442 | 0.070 |
Why?
| Magnetic Resonance Angiography | 1 | 2008 | 234 | 0.070 |
Why?
| Forearm | 2 | 2017 | 117 | 0.060 |
Why?
| Triglycerides | 3 | 2013 | 527 | 0.060 |
Why?
| Protective Factors | 2 | 2016 | 91 | 0.060 |
Why?
| Contrast Media | 1 | 2008 | 393 | 0.060 |
Why?
| Carcinoma, Non-Small-Cell Lung | 1 | 2013 | 1049 | 0.060 |
Why?
| Autoimmune Diseases | 1 | 2009 | 426 | 0.060 |
Why?
| Outpatients | 1 | 2008 | 366 | 0.060 |
Why?
| Middle Cerebral Artery | 1 | 2025 | 43 | 0.060 |
Why?
| Immunity, Innate | 1 | 2011 | 803 | 0.060 |
Why?
| Calcifediol | 1 | 2024 | 31 | 0.060 |
Why?
| Phagocytosis | 1 | 2006 | 362 | 0.060 |
Why?
| Ascorbic Acid | 1 | 2025 | 120 | 0.060 |
Why?
| Genotype | 2 | 2020 | 1833 | 0.060 |
Why?
| Fatty Acid-Binding Proteins | 1 | 2024 | 68 | 0.050 |
Why?
| Enzyme-Linked Immunosorbent Assay | 2 | 2016 | 832 | 0.050 |
Why?
| Hemodialysis, Home | 1 | 2023 | 8 | 0.050 |
Why?
| Nicotinamide Mononucleotide | 1 | 2023 | 9 | 0.050 |
Why?
| Respiratory Therapy | 1 | 2023 | 23 | 0.050 |
Why?
| Self-Help Groups | 1 | 2023 | 34 | 0.050 |
Why?
| B7-1 Antigen | 1 | 2023 | 55 | 0.050 |
Why?
| Cysts | 1 | 2024 | 108 | 0.050 |
Why?
| Kidney Glomerulus | 1 | 2003 | 109 | 0.050 |
Why?
| Ultrasonography, Doppler | 1 | 2003 | 118 | 0.050 |
Why?
| Caregivers | 2 | 2020 | 802 | 0.050 |
Why?
| Tryptophan Oxygenase | 1 | 2023 | 34 | 0.050 |
Why?
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2023 | 55 | 0.050 |
Why?
| Hand Strength | 1 | 2023 | 113 | 0.050 |
Why?
| Antineoplastic Agents | 1 | 2013 | 2045 | 0.050 |
Why?
| Muscles | 1 | 2023 | 320 | 0.050 |
Why?
| NADPH Oxidases | 2 | 2013 | 108 | 0.050 |
Why?
| Administration, Oral | 1 | 2024 | 785 | 0.050 |
Why?
| Least-Squares Analysis | 2 | 2012 | 78 | 0.050 |
Why?
| Midazolam | 1 | 2022 | 53 | 0.050 |
Why?
| Waist Circumference | 2 | 2012 | 138 | 0.050 |
Why?
| Blood Flow Velocity | 1 | 2023 | 406 | 0.050 |
Why?
| Vulnerable Populations | 1 | 2022 | 156 | 0.050 |
Why?
| Endocannabinoids | 1 | 2022 | 53 | 0.050 |
Why?
| Mice, Mutant Strains | 1 | 2022 | 297 | 0.050 |
Why?
| Activating Transcription Factor 4 | 1 | 2021 | 20 | 0.050 |
Why?
| Carbon Dioxide | 1 | 2023 | 259 | 0.050 |
Why?
| B7-H1 Antigen | 1 | 2023 | 195 | 0.050 |
Why?
| Pulmonary Disease, Chronic Obstructive | 1 | 2009 | 983 | 0.050 |
Why?
| Social Isolation | 1 | 2021 | 59 | 0.040 |
Why?
| Clinical Trials as Topic | 2 | 2019 | 1003 | 0.040 |
Why?
| Hematinics | 1 | 2020 | 20 | 0.040 |
Why?
| Hepcidins | 1 | 2020 | 22 | 0.040 |
Why?
| Phenotype | 2 | 2022 | 3071 | 0.040 |
Why?
| Acute Disease | 2 | 2017 | 978 | 0.040 |
Why?
| Databases, Genetic | 1 | 2022 | 230 | 0.040 |
Why?
| Administrative Personnel | 1 | 2020 | 28 | 0.040 |
Why?
| Nephrologists | 1 | 2020 | 12 | 0.040 |
Why?
| Hypoglycemic Agents | 2 | 2024 | 1220 | 0.040 |
Why?
| Calcium Compounds | 1 | 2020 | 4 | 0.040 |
Why?
| Asia | 1 | 2020 | 58 | 0.040 |
Why?
| Combined Modality Therapy | 1 | 2023 | 1198 | 0.040 |
Why?
| California | 2 | 2012 | 400 | 0.040 |
Why?
| Biopsy | 1 | 2003 | 1084 | 0.040 |
Why?
| Africa | 1 | 2020 | 99 | 0.040 |
Why?
| Disease Models, Animal | 2 | 2022 | 4056 | 0.040 |
Why?
| Serum Albumin | 1 | 2020 | 148 | 0.040 |
Why?
| HIV Infections | 1 | 2014 | 2721 | 0.040 |
Why?
| Magnetic Resonance Imaging, Cine | 1 | 2021 | 185 | 0.040 |
Why?
| Vitamin B Complex | 1 | 2020 | 41 | 0.040 |
Why?
| Social Stigma | 1 | 2021 | 117 | 0.040 |
Why?
| Stakeholder Participation | 1 | 2020 | 75 | 0.040 |
Why?
| Matched-Pair Analysis | 1 | 2019 | 40 | 0.040 |
Why?
| Drug Monitoring | 1 | 2021 | 215 | 0.040 |
Why?
| Drug Interactions | 1 | 2021 | 393 | 0.040 |
Why?
| Health Literacy | 1 | 2021 | 159 | 0.040 |
Why?
| Registries | 2 | 2021 | 1895 | 0.040 |
Why?
| Intracranial Aneurysm | 1 | 2020 | 95 | 0.040 |
Why?
| Models, Animal | 1 | 2021 | 376 | 0.040 |
Why?
| Glucuronidase | 1 | 2018 | 44 | 0.040 |
Why?
| Renal Circulation | 1 | 2018 | 57 | 0.040 |
Why?
| Ligands | 1 | 2020 | 620 | 0.040 |
Why?
| Tandem Mass Spectrometry | 1 | 2022 | 522 | 0.040 |
Why?
| Patients | 1 | 2020 | 167 | 0.040 |
Why?
| Urban Population | 1 | 2021 | 441 | 0.040 |
Why?
| Symptom Flare Up | 1 | 2018 | 38 | 0.040 |
Why?
| Self Concept | 1 | 2020 | 237 | 0.040 |
Why?
| Sodium Chloride Symporter Inhibitors | 1 | 2018 | 9 | 0.040 |
Why?
| Career Choice | 1 | 2020 | 206 | 0.040 |
Why?
| Aftercare | 1 | 2020 | 203 | 0.040 |
Why?
| Publications | 1 | 2018 | 41 | 0.040 |
Why?
| Pyridinium Compounds | 1 | 2018 | 25 | 0.040 |
Why?
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2019 | 149 | 0.040 |
Why?
| Fathers | 1 | 2018 | 49 | 0.040 |
Why?
| Fibrosis | 1 | 2020 | 520 | 0.030 |
Why?
| Intelligence Tests | 1 | 2017 | 57 | 0.030 |
Why?
| Mitral Valve Stenosis | 1 | 2017 | 18 | 0.030 |
Why?
| Healthy Volunteers | 1 | 2018 | 200 | 0.030 |
Why?
| NF-kappa B | 2 | 2012 | 663 | 0.030 |
Why?
| Activities of Daily Living | 1 | 2020 | 381 | 0.030 |
Why?
| Interleukin-18 | 1 | 2018 | 237 | 0.030 |
Why?
| Cholesterol | 1 | 2019 | 412 | 0.030 |
Why?
| Calcium Channel Blockers | 1 | 2018 | 161 | 0.030 |
Why?
| Consensus | 1 | 2020 | 615 | 0.030 |
Why?
| Energy Intake | 1 | 2020 | 461 | 0.030 |
Why?
| Femur Neck | 1 | 2017 | 60 | 0.030 |
Why?
| Safety-net Providers | 1 | 2018 | 109 | 0.030 |
Why?
| Quality of Health Care | 1 | 2021 | 602 | 0.030 |
Why?
| Diuretics | 1 | 2016 | 75 | 0.030 |
Why?
| Patient Reported Outcome Measures | 1 | 2020 | 372 | 0.030 |
Why?
| Antineoplastic Agents, Immunological | 1 | 2018 | 181 | 0.030 |
Why?
| Methemoglobin | 1 | 2015 | 20 | 0.030 |
Why?
| Sensitivity and Specificity | 2 | 2010 | 1833 | 0.030 |
Why?
| Hip Joint | 1 | 2017 | 158 | 0.030 |
Why?
| Program Development | 1 | 2018 | 355 | 0.030 |
Why?
| Delivery of Health Care | 1 | 2022 | 892 | 0.030 |
Why?
| Chromatography, Liquid | 1 | 2017 | 423 | 0.030 |
Why?
| White Matter | 1 | 2017 | 135 | 0.030 |
Why?
| Anthropometry | 1 | 2016 | 204 | 0.030 |
Why?
| Research | 1 | 2018 | 416 | 0.030 |
Why?
| Interviews as Topic | 1 | 2018 | 703 | 0.030 |
Why?
| Elasticity | 1 | 2015 | 194 | 0.030 |
Why?
| Renal Reabsorption | 1 | 2014 | 4 | 0.030 |
Why?
| Gastrointestinal Absorption | 1 | 2014 | 5 | 0.030 |
Why?
| Urinalysis | 1 | 2015 | 75 | 0.030 |
Why?
| Renal Elimination | 1 | 2014 | 6 | 0.030 |
Why?
| Vasodilator Agents | 1 | 2017 | 326 | 0.030 |
Why?
| Prenatal Diagnosis | 1 | 2016 | 190 | 0.030 |
Why?
| Age of Onset | 1 | 2016 | 495 | 0.030 |
Why?
| Actigraphy | 1 | 2015 | 98 | 0.030 |
Why?
| Ketocholesterols | 1 | 2014 | 7 | 0.030 |
Why?
| France | 1 | 2014 | 29 | 0.030 |
Why?
| Research Design | 2 | 2011 | 1042 | 0.030 |
Why?
| Patient Satisfaction | 1 | 2019 | 631 | 0.030 |
Why?
| Societies, Medical | 1 | 2018 | 744 | 0.030 |
Why?
| Needs Assessment | 1 | 2017 | 357 | 0.030 |
Why?
| Ultrasonography, Doppler, Duplex | 1 | 2014 | 43 | 0.030 |
Why?
| Ezetimibe | 1 | 2014 | 25 | 0.030 |
Why?
| Prostaglandins | 1 | 2014 | 93 | 0.030 |
Why?
| Dilatation, Pathologic | 1 | 2014 | 60 | 0.030 |
Why?
| Azetidines | 1 | 2014 | 40 | 0.030 |
Why?
| Osteoporosis | 1 | 2017 | 229 | 0.030 |
Why?
| Apolipoproteins E | 1 | 2014 | 77 | 0.030 |
Why?
| F2-Isoprostanes | 1 | 2013 | 20 | 0.030 |
Why?
| Immunotherapy | 1 | 2018 | 590 | 0.030 |
Why?
| Aortic Valve | 1 | 2017 | 347 | 0.030 |
Why?
| Health Personnel | 1 | 2020 | 648 | 0.030 |
Why?
| Arachidonate 12-Lipoxygenase | 1 | 2013 | 17 | 0.030 |
Why?
| Early Medical Intervention | 1 | 2014 | 57 | 0.030 |
Why?
| Arachidonate 15-Lipoxygenase | 1 | 2013 | 23 | 0.030 |
Why?
| Acute Coronary Syndrome | 1 | 2017 | 267 | 0.030 |
Why?
| Erythropoiesis | 1 | 2013 | 51 | 0.030 |
Why?
| Cells, Cultured | 1 | 2021 | 4075 | 0.030 |
Why?
| Pulse | 1 | 2013 | 23 | 0.030 |
Why?
| Program Evaluation | 1 | 2018 | 872 | 0.030 |
Why?
| Executive Function | 1 | 2018 | 431 | 0.030 |
Why?
| Genetic Predisposition to Disease | 1 | 2022 | 2272 | 0.030 |
Why?
| Signal Transduction | 2 | 2018 | 4919 | 0.030 |
Why?
| Mice, Transgenic | 1 | 2018 | 2117 | 0.030 |
Why?
| Immunoblotting | 1 | 2013 | 305 | 0.030 |
Why?
| Tenofovir | 1 | 2014 | 231 | 0.030 |
Why?
| Albumins | 1 | 2013 | 103 | 0.030 |
Why?
| Fluorescent Antibody Technique | 1 | 2013 | 375 | 0.030 |
Why?
| Cell Line | 1 | 2018 | 2775 | 0.030 |
Why?
| Random Allocation | 1 | 2013 | 346 | 0.030 |
Why?
| Drug Administration Schedule | 1 | 2014 | 767 | 0.020 |
Why?
| Xanthine Oxidase | 1 | 2012 | 78 | 0.020 |
Why?
| Biological Availability | 1 | 2012 | 147 | 0.020 |
Why?
| Germany | 1 | 2012 | 100 | 0.020 |
Why?
| Blood Glucose | 2 | 2012 | 2098 | 0.020 |
Why?
| Aspartate Aminotransferases | 1 | 2012 | 88 | 0.020 |
Why?
| Microcirculation | 1 | 2012 | 145 | 0.020 |
Why?
| Epithelial Cells | 1 | 2018 | 1064 | 0.020 |
Why?
| Insulin | 2 | 2013 | 2325 | 0.020 |
Why?
| Ventricular Remodeling | 1 | 2014 | 255 | 0.020 |
Why?
| Stress, Psychological | 1 | 2020 | 1065 | 0.020 |
Why?
| Mothers | 1 | 2018 | 730 | 0.020 |
Why?
| In Vitro Techniques | 1 | 2013 | 1085 | 0.020 |
Why?
| Lipoproteins, LDL | 1 | 2012 | 127 | 0.020 |
Why?
| Perioperative Period | 1 | 2011 | 49 | 0.020 |
Why?
| Metoprolol | 1 | 2011 | 39 | 0.020 |
Why?
| Nitroglycerin | 1 | 2010 | 17 | 0.020 |
Why?
| Aortic Diseases | 1 | 2012 | 113 | 0.020 |
Why?
| Salicylates | 1 | 2010 | 30 | 0.020 |
Why?
| Genetic Association Studies | 1 | 2012 | 361 | 0.020 |
Why?
| Arteries | 1 | 2012 | 265 | 0.020 |
Why?
| Receptors, Calcitriol | 1 | 2010 | 53 | 0.020 |
Why?
| Stroke Volume | 1 | 2013 | 592 | 0.020 |
Why?
| Lipids | 1 | 2014 | 625 | 0.020 |
Why?
| Infusions, Intravenous | 1 | 2011 | 399 | 0.020 |
Why?
| Sunlight | 1 | 2010 | 72 | 0.020 |
Why?
| Area Under Curve | 1 | 2010 | 304 | 0.020 |
Why?
| Life Style | 1 | 2012 | 459 | 0.020 |
Why?
| Superoxide Dismutase | 1 | 2012 | 342 | 0.020 |
Why?
| Elective Surgical Procedures | 1 | 2010 | 164 | 0.020 |
Why?
| Echocardiography | 1 | 2012 | 629 | 0.020 |
Why?
| Thyroid Function Tests | 1 | 2009 | 14 | 0.020 |
Why?
| Cystatins | 1 | 2008 | 6 | 0.020 |
Why?
| ROC Curve | 1 | 2010 | 502 | 0.020 |
Why?
| Myocardial Ischemia | 1 | 2010 | 258 | 0.020 |
Why?
| Cardiovascular Surgical Procedures | 1 | 2008 | 28 | 0.020 |
Why?
| Rats, Sprague-Dawley | 1 | 2013 | 2395 | 0.020 |
Why?
| Dobutamine | 1 | 2007 | 37 | 0.020 |
Why?
| Morbidity | 1 | 2008 | 299 | 0.020 |
Why?
| Angioplasty, Balloon, Coronary | 1 | 2008 | 140 | 0.020 |
Why?
| Emergency Service, Hospital | 1 | 2018 | 1896 | 0.020 |
Why?
| Biomarkers, Tumor | 1 | 2013 | 1161 | 0.020 |
Why?
| Perioperative Care | 1 | 2008 | 151 | 0.020 |
Why?
| Exercise | 1 | 2018 | 1925 | 0.020 |
Why?
| Electronic Health Records | 1 | 2013 | 970 | 0.020 |
Why?
| Hemodynamics | 1 | 2011 | 1090 | 0.020 |
Why?
| Rats | 1 | 2013 | 5479 | 0.010 |
Why?
| Ventricular Function, Left | 1 | 2007 | 527 | 0.010 |
Why?
| Genome-Wide Association Study | 1 | 2010 | 1326 | 0.010 |
Why?
| Surveys and Questionnaires | 1 | 2016 | 5382 | 0.010 |
Why?
|
|
Chonchol's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|